Ed T Buurman


Affiliation: AstraZeneca R and D


  1. Buurman E, Andrews B, Gao N, Hu J, Keating T, Lahiri S, et al. In vitro validation of acetyltransferase activity of GlmU as an antibacterial target in Haemophilus influenzae. J Biol Chem. 2011;286:40734-42 pubmed publisher
    ..This is the first example of antimicrobial compounds mediating their growth inhibitory effects specifically via GlmU. ..
  2. Abibi A, Ferguson A, Fleming P, Gao N, Hajec L, Hu J, et al. The role of a novel auxiliary pocket in bacterial phenylalanyl-tRNA synthetase druggability. J Biol Chem. 2014;289:21651-62 pubmed publisher
    ..Three viable inhibitor-resistant mutants were mapped to this pocket, suggesting that this region is a potential liability for drug discovery. ..
  3. Buurman E, McLaggan D, Naprstek J, Epstein W. Multiple paths for nonphysiological transport of K+ in Escherichia coli. J Bacteriol. 2004;186:4238-45 pubmed
    ..These results support the view that TrkF is composed of multiple, "aberrant" K+ transport activities, i.e., paths that, regardless of their physiological function, allow K+ to cross the cell membrane by a uniport process. ..